A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: The most common cause of polyneuropathy is diabetes mellitus. Neuropathic pain is seen in 26% of diabetic population. Therapeutic techniques for this disease can become challenging. Method: This study was a prospective comparative double-blind randomized study which was conducted during an eight-week period. Totally, 104 painful diabetic peripheral polyneuropathy (PDPP) patients who had a minimum Visual Analog Scale (VAS) of 40 millimeters, received no pain-controlling medication, and had no other severe disease at its final stage were randomly assigned to two groups (n=52) through the four block method. One group received Duloxetine and the other received Gabapentin. The effectiveness was measured through primary effectiveness (VAS scale) and secondary effectiveness (Sleep Interference Score, and Clinical Global Impression of Change (CGIC)). Medication compliance was assessed by enumerating the number of patients who refused treatment because of side effects. The Fisher’s exact T-test and ANOVA were used for data analysis. This study was approved by the Ethics Committee of Jundishapur, University of Medical sciences Ahvaz, Iran, under reference number: IR.AJUMS.REC.1395.78. In addition, this study was registered and approved in the Iranian Registry of Clinical Trials (IRCT ID: IRCT20161023030455N2) (http://irct.ir/). Results: VAS, Sleep Interference Score, and CGIC were significantly improved (P<0.05) through time in both groups, [For GBP: VAS Baseline, =64±20.03, VAS week1, =55.32±18.76, VAS week4, =44.68±15.82, VAS week8, =39.43±14.32; For DLX: VAS Base-line, =62±21.18, VAS week1, =58.76±20.37, VAS week4, =45.84±16.21, VAS week8, =36.78±15.62] while a significant difference between the two groups was not observed (P<0.05). However, such significant improvements were not observed in the Duloxetine group at the end of the first week (P=674). Improvement in Sleep Interference Score and CGIC were similar to the results for the VAS scale. Side effects in the Duloxetine group (n=2) compared to the Gabapentin group (n=9) were significantly less (P<0.001). As a result, medication acceptance in the Duloxetine group (n=47) was significantly better than the Gabapentin (n=41) group (P<0.001). Conclusion: Both Duloxetine and Gabapentin are effective for the treatment of PDPP. On the one hand, Gabapentin shows the effect earlier while has more side effects. Conversely, Duloxetine has better medication compliance. Trial registration: The method of this study was approved by the Ethics Committee of Jundishapur University of Medical Sciences, Ahvaz, Iran, under reference number: IR.AJUMS.REC.1395.78. In addition, this study was registered and approved in the Iranian Registry of Clinical Trials (IRCT ID: IRCT20161023030455N2) (http://irct.ir/). Keywords: Duloxetine, Gabapentin, painful diabetic peripheral neuropathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, among pharmacological options, pregabalin588–598 and duloxetine594,595,599,600 are oral agents that have received regulatory approval for the treatment of neuropathic pain associated with DPN by the FDA and are effective for DPN pain reduction when using patient-reported outcomes.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [596]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Üstün, Y. E. (2019) · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · Cited by 169,581
Boulton, A. J. M., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., Malik, R. A., Maser, R. E., Sosenko, J. M., & Ziegler, D. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.956 · Cited by 1,859
Backonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533 · cited 2×
“A large placebo-control study showed that Gabapentin is effective in the treatment of painful diabetic peripheral neuropathy.(1,15) A recent randomized, multi-center placebo-controlled study showed that Duloxetine was more effective than placebo in controlling PPP and it improved VAS mean score by 50% in 24 hrs.”
BackgroundYoung, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502 · cited 1×
“10 Since neuropathic symptoms intensify at night, sleep disorders happen and this not only affects the patient ’ s quality of life, but also worsens his/her diabetes.”
BackgroundAssociation of sleep time with diabetes mellitus and impaired glucose tolerance
Gottlieb, D. J., Punjabi, N. M., Newman, A. B., Resnick, H. E., Redline, S., Baldwin, C. M., & Nieto, F. J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.863 · Cited by 927 · cited 1×
“11 A mellitus diabetic patient who complains of foot or lower limb pain is normally diagnosed with painful diabetic peripheral neuropathy.”
BackgroundDuloxetine vs. placebo in patients with painful diabetic neuropathy
Goldstein, D. J., Lu, Y., Detke, M. J., Lee, T. C., & Iyengar, S. (2005) · Pain · doi:10.1016/j.pain.2005.03.029 · Cited by 858 · cited 1×
“…placebo-controlled study showed that Duloxetine was more effective than placebo in controlling PPP and it improved VAS mean score by 50% in 24 hrs. 26 The results of the above studies are in line with the results of this study and show that both medications are effective in treating pain of the…”
ResultThe Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes
Davies, M., Brophy, S., Williams, R., & Taylor, A. (2006) · Diabetes Care · doi:10.2337/dc05-2228 · Cited by 746
Bymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
The spectrum of neuropathy in diabetes and impaired glucose tolerance
Sumner, C. J., Sheth, S., Griffin, J. W., Cornblath, D. R., & Polydefkis, M. (2003) · Neurology · doi:10.1212/wnl.60.1.108 · Cited by 708 · cited 1×
“14 The basis of treatment and control of all diabetic complications is glucose control.”
BackgroundThe mechanisms of action of gabapentin and pregabalin
SILLS, G. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.003 · Cited by 671 · cited 1×
“Gabapentin acts like Pregabalin by connecting to the a-2d subunit of voltage gated calcium channels.(17)”
BackgroundSaid, G. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0504 · Cited by 615 · cited 1×
“This form of diabetic neuropathy is axonal and its progress depends on the length of the nerve fiber, ie, the longer the nerve fiber the sooner it will be engaged (the feet are engaged first).(6) A form of neuropathy is seen among 60–70% of diabetic patients.”
BackgroundPainful diabetic polyneuropathy: epidemiology, pain description, and quality of life
Galer, B. S., Gianas, A., & Jensen, M. P. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00112-6 · Cited by 601
Epidemiology and Impact on Quality of Life of Postherpetic Neuralgia and Painful Diabetic Neuropathy
Schmader, K. E. (2002) · The Clinical Journal of Pain · doi:10.1097/00002508-200211000-00002 · Cited by 550
Dyck, P. J., Albers, J. W., Andersen, H., Arezzo, J. C., Biessels, G., Bril, V., Feldman, E. L., Litchy, W. J., O'Brien, P. C., Russell, J. W., et al. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1226 · Cited by 497
Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials
Backonja, M., & Glanzman, R. L. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90011-7 · Cited by 425 · cited 1×
“As an anticonvulsant medication, Gabapentin is commonly used for treatment of neuropathic diabetes.(1,16)”
BackgroundDiabetic peripheral neuropathic pain: clinical and quality-of-life issues
Argoff, C. E., Cole, B. E., Fishbain, D. A., & Irving, G. A. (2006) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61474-2 · Cited by 256
Diabetic neuropathies:A statement by the American Diabetes Association
Xie, Y. (2009) · Intern J Endocrinol Metab · doi:10.3760/cma.j.issn.1673-4157.2009.06.020 · Cited by 229
Boyle, J., Eriksson, M. E. V., Gribble, L., Gouni, R., Johnsen, S., Coppini, D. V., & Kerr, D. (2012) · Diabetes Care · doi:10.2337/dc12-0656 · Cited by 225
Quilici, S., Chancellor, J., Löthgren, M., Simon, D., Said, G., Le, T. K., Garcia-Cebrian, A., & Monz, B. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-6 · Cited by 223 · cited 1×
“27 However, these studies were not done on Iranian patients, and the present study shows that the side effects of Gabapentin are signi fi cantly higher than Duloxetine for Iranians.”
BackgroundLY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake
Wong, D. T., Bymaster, F. P., Mayle, D. A., Reid, L. R., Krushinski, J. H., & Robertson, D. W. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.4 · Cited by 222
Diabetic neuropathy: pathogenesis and therapy
Vinik, A. I. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00009-1 · Cited by 211
Consensus Guidelines: Treatment Planning and Options
Argoff, C. E., Backonja, M.-M., Belgrade, M. J., Bennett, G. J., Clark, M. R., Cole, B. E., Fishbain, D. A., Irving, G. A., McCarberg, B. H., & McLean, M. J. (2006) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61475-4 · Cited by 158 · cited 1×
“22 A limited number of studies have directly (head to head) compared the effectiveness of the two medications used for treating PDPP. 23 This study showed that VAS signi fi cantly decreased in both groups and the two medications were both effective for treating the symptoms of painful diabetic…”
BackgroundBačkonja, M., Beydoun, A. A., Edwards, K. R., Schwartz, S. L., Fonseca, V. A., HES, M., MOREAUX, L. L., & Garofalo, E. (1999) · Survey of Anesthesiology · doi:10.1097/00132586-199908000-00055 · Cited by 153
Diabetic Painful Neuropathy: Current and Future Treatment Options
Chong, M. S., & Hester, J. (2007) · Drugs · doi:10.2165/00003495-200767040-00006 · Cited by 141
Tanenberg, R. J., Irving, G. A., Risser, R. C., AHL, J. S. B., Robinson, M. J., Skljarevski, V., & Malcolm, S. K. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0681 · Cited by 140
Amthor, K.-F., Dahl‐Jørgensen, K., Tj, B., Heier, M., Sandvik, L., Aagen�s, �., & Hanssen, K. F. (1994) · Diabetologia · doi:10.1007/bf00403376 · Cited by 110 · cited 1×
“21 Consensus-based treatment guidelines recommended both pregabalin and duloxetine for managing PDPP patients as fi rst-line medications.”
MethodKulkarni, C., Devi, P., Madhu, K., Ganapathi, B., Sarma, G., & John, L. J. (2012) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.91867 · Cited by 63 · cited 4×
“A limited number of studies have directly (head to head) compared the effectiveness of the two medications used for treating PDPP.(23) This study showed that VAS significantly decreased in both groups and the two medications were both effective for treating the symptoms of painful diabetic peripheral polyneuropathy.”
BackgroundResultInfluentialA 52-Year-Old Woman With Disabling Peripheral Neuropathy: Review of Diabetic Polyneuropathy
Rutkove, S. B. (2009) · JAMA · doi:10.1001/jama.2009.1377 · Cited by 34 · cited 1×
“12,13 A link between the intensity of disorder in glucose metabolism and neuropathy development has been shown in studies on patients who represented a series of disorders like the glucose tolerance test, ie, the effect of hyperglycemia in creating neuropathy in patients who showed disorders in…”
BackgroundAmthor, K.-F., Dahl-J�rgensen, K., Tj, B., et al. (1994) · Diabetologia · doi:10.1007/s001250050150 · Cited by 9
Robinson, M. J., AHL, J. S. B., Meyers, A. L., McCarberg, B. H., & Iyengar, S. (2011) · Current Drug Therapy · doi:10.2174/157488511795304903 · Cited by 4
Research works printed but not linked: 1
- [12]King SA. Diabetic peripheral neuropathic pain: effective management. Consultant. 2008; 48(11): 825.
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Antidepressants for pain management in adults with chronic pain: a network meta-analysis
Birkinshaw, H., Friedrich, C., Cole, P., Eccleston, C., Serfaty, M. A., Stewart, G. B., White, S. P., Moore, A., Phillippo, D., & Pincus, T. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014682.pub2 · Cited by 222
Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review
Liampas, A., Rekatsina, M., Vadalouca, A., Paladini, A., Varrassi, G., & Zis, P. (2020) · Pain and Therapy · doi:10.1007/s40122-020-00210-3 · Cited by 85
Prevention and Management Strategies for Diabetic Neuropathy
Smith, S., Normahani, P., Lane, T. R. A., Hohenschurz‐Schmidt, D., Oliver, N. S., & Davies, A. H. (2022) · Life · doi:10.3390/life12081185 · Cited by 98
The Treatment of Painful Diabetic Neuropathy
SLOAN, G. P., Alam, U., Selvarajah, D., & Tesfaye, S. H. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210707112413 · Cited by 71
Metadata
- Authors
- Majdinasab, N., Kaveyani, H., & Azizi, M.
- Affiliations
- Ahvaz Jundishapur University of Medical Sciences (IR)
- Corresponding author
- Kaveyani, Hossein
- ORCID
- Majdinasab, Nastaran
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-06
- Volume
- Volume 13
- Pages
- 1985-1992
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC6588725
- OpenAlex
- W2952712394
- Cited by
- 54
- References
- 30
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 19 · 2021: 8 · 2020: 4
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Ahvaz Jundishapur University of Medical Sciences
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Keywords
- diabetic neuropathic pain, duloxetine, gabapentin, sleep interference, medication adherence, adverse effects, antidepressants, antiepileptic drugs, pain intensity, Clinical Global Impression of Change, visual analogue scale, treatment effectiveness comparison, sleep quality, quality of life, diabetes complications
- MeSH terms
- Duloxetine Hydrochloride, Gabapentin, Administration, Oral, Adolescent, Adult, Aged, Analgesics, Diabetic Neuropathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuralgia, Prospective Studies, Young Adult, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
